Windlas Biotech Ltd (WINDLAS) Q4FY26 Management Mirror - Mar-2026 Qtr
Capacity & Plant-6 Commissioning
Management anticipates Plant 6 commercialization by Sep'26, driving total revenue capacity to INR 1,100 crores (INR 1,000 crores excluding injectables) with a further 10% to 15% efficiency upside expected subsequently in the Mar'26 Qtr update. This maintains the Dec'25 Qtr projection of achieving mechanical completion by Mar'26 and INR 1,000 crores ex-injectables capacity, following the Sep'25 Qtr expectation to commission the facility within FY26. [Status: Reaffirmed]
4 more themes on the ELITE plan.